Insider Selling: Scholar Rock (NASDAQ:SRRK) Insider Sells $695,885.58 in Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Mo Qatanani sold 14,898 shares of the stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $46.71, for a total transaction of $695,885.58. Following the completion of the transaction, the insider directly owned 85,660 shares of the company’s stock, valued at approximately $4,001,178.60. The trade was a 14.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Mo Qatanani also recently made the following trade(s):

• On Friday, January 16th, Mo Qatanani sold 8,406 shares of Scholar Rock stock. The shares were sold at an average price of $44.48, for a total value of $373,898.88.
• On Wednesday, January 14th, Mo Qatanani sold 13,112 shares of Scholar Rock stock. The stock was sold at an average price of $45.20, for a total value of $592,662.40.
• On Thursday, December 4th, Mo Qatanani sold 136,462 shares of Scholar Rock stock. The shares were sold at an average price of $45.21, for a total value of $6,169,447.02.

Scholar Rock Stock Down 7.3%

Shares of SRRK opened at $44.29 on Monday. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41. Scholar Rock Holding Corporation has a 52-week low of $22.71 and a 52-week high of $48.28. The company has a market cap of $4.52 billion, a PE ratio of -14.06 and a beta of 0.63. The business has a fifty day moving average of $43.73 and a 200 day moving average of $37.32.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Friday, November 14th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same period in the previous year, the company posted ($0.66) EPS. On average, sell-side analysts expect that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Analysts Set New Price Targets

SRRK has been the topic of several recent analyst reports. Bank of America started coverage on Scholar Rock in a report on Thursday, October 9th. They issued a “buy” rating and a $53.00 price target on the stock. UBS Group assumed coverage on Scholar Rock in a research report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price objective on the stock. JPMorgan Chase & Co. lifted their target price on Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. BMO Capital Markets reissued an “outperform” rating and set a $50.00 target price on shares of Scholar Rock in a research note on Friday, November 14th. Finally, Barclays raised their price target on shares of Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Four research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $50.14.

Hedge Funds Weigh In On Scholar Rock

Several institutional investors have recently bought and sold shares of SRRK. Ramirez Asset Management Inc. purchased a new stake in Scholar Rock during the third quarter worth $37,000. Penserra Capital Management LLC purchased a new stake in shares of Scholar Rock during the 3rd quarter worth $56,000. Strs Ohio bought a new stake in Scholar Rock during the first quarter valued at about $77,000. Bessemer Group Inc. grew its stake in Scholar Rock by 970.0% in the third quarter. Bessemer Group Inc. now owns 2,322 shares of the company’s stock valued at $86,000 after purchasing an additional 2,105 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC purchased a new position in Scholar Rock in the second quarter valued at about $94,000. 91.08% of the stock is owned by hedge funds and other institutional investors.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).